Similar articles

• Combination chemotherapy for non-small cell bronchogenic carcinoma with bleomycin, doxorubicin, methotrexate, and cis-dichlorodiammineplatinum(II) (BAMP).

  Vogl SE, Wollner D, Kaplan BH, Berenzweig M. Vogl SE, et al. Cancer Treat Rep. 1980 Apr-May;64(4-5):717-9. Cancer Treat Rep. 1980. PMID: 6159081 No abstract available.
• Bleomycin, vincristine, and methotrexate (BOM) in squamous cell carcinoma of the lung: a phase II study.

  Libretti A, Piazza E, Scanni A, Tomirotti M, Biraghi M, Scapaticci R, Bianchi C, Restelli G, Scarpazza G, Calzavara MP, Marsoni S, Morasca L. Libretti A, et al. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):171-2. Cancer Treat Rep. 1981. PMID: 6164485 No abstract available.
• [Comparative study of 2 different chemotherapeutic combinations in epidermoid carcinoma of the lung. Preliminary results].

  Pipino G, Germiniani R, Maione G, Fazio FM. Pipino G, et al. Arch Sci Med (Torino). 1983 Apr-Jun;140(2):135-8. Arch Sci Med (Torino). 1983. PMID: 6192792 Italian. No abstract available.
• Current status of American studies with bleomycin.

  Carter SK, Blum RH. Carter SK, et al. Prog Biochem Pharmacol. 1976;11:158-71. Prog Biochem Pharmacol. 1976. PMID: 63960 Review. No abstract available.
• Controlled studies with bleomycin in solid tumors and lymphomas.

  Bonadonna G, Tancini G, Bajetta E. Bonadonna G, et al. Prog Biochem Pharmacol. 1976;11:172-84. Prog Biochem Pharmacol. 1976. PMID: 63961 Review. No abstract available.